Opendata, web and dolomites

ImmunoFarm

IgA-based oral therapy for protection of piglets against infection with enterotoxigenic E. coli.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ImmunoFarm project word cloud

Explore the words cloud of the ImmunoFarm project. It provides you a very rough idea of what is the project "ImmunoFarm" about.

cocktails    etec    immunity    seed    antibody    prophylactic    group    antibodies    f18    feed    formulation    genes    performed    industry    siga    biosafe    transient    immunotherapy    seeds    vitro    display    arabidopsis    postweaning    fimbriae    anti    f4    post    assays    maternal    vivo    piglets    rearing    pwd    agent    formulations    passive    enterotoxigenic    negative    world    infections    host    transferred    additive    resistance    thaliana    rest    benthamiana    abundance    transformants    soya    elite    economic    nicotiana    fight    strains    mucosal    oligoclonal    global    synergistic    responsible    predominantly    regular    prolong    caused    antibiotics    scalable    lactogenic    losses    receiving    treatment    villus    expression    forbidden    twenty    groups    diarrhoea    format    pigs    coli    effect    obtain    strategy    engineered    first    prophylaxis    except    surfaces    neutralisation    pig    bulk    platform    domains    vhhs    adhesion    weaning    phage    illness   

Project "ImmunoFarm" data sheet

The following table provides information about the project.

Coordinator
VIB 

Organization address
address: RIJVISSCHESTRAAT 120
city: ZWIJNAARDE - GENT
postcode: 9052
website: www.vib.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Project website https://www.facebook.com/ImmunoFarm-356855711413541/
 Total cost 160˙800 €
 EC max contribution 160˙800 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2017-08-13

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VIB BE (ZWIJNAARDE - GENT) coordinator 160˙800.00

Map

 Project objective

Postweaning diarrhoea (PWD) in pigs is responsible for important economic losses in the global pig rearing industry. This illness is predominantly caused by enterotoxigenic E. coli strains carrying the F4 (ETEC-F4) and F18 (ETEC-F18) fimbriae. There is no treatment available to fight PWD except using antibiotics. However, the prophylactic use of antibiotics is forbidden in Europe and is expected to become forbidden in the rest of the world because of increasing abundance of resistance genes. Delivery of sIgA to mucosal surfaces as passive immunotherapy agent is a very promising strategy to prolong maternal lactogenic immunity against post-weaning infections. The aim of this project is to produce sIgA-like anti-ETEC antibodies in a cost-effective platform. Twenty different anti ETEC-F18 antibodies in a sIgA-like format will be engineered from phage display-selected variable domains (VHHs) currently available in the host institute. The synergistic or additive neutralisation effect of oligoclonal antibody cocktails will be evaluated using ETEC-F18 in vitro villus adhesion assays. The different antibodies will be produced first by transient expression in Nicotiana benthamiana and second in seeds of Arabidopsis thaliana transformants. An in vivo ETEC-F18 challenge will then be performed using two groups of piglets, one receiving the most effective seed-derived feed formulations and the other one receiving regular feed (negative control group). The sIgA antibodies of the elite oligoclonal formulation will then be transferred to biosafe soya seeds as production platform. These steps will lead towards the development of scalable procedures to obtain a cost effective bulk production of a feed based prophylaxis against ETEC.

 Publications

year authors and title journal last update
List of publications.
2016 Vikram Virdi, Paloma Juarez, Veronique Boudolf, Ann Depicker
Recombinant IgA production for mucosal passive immunization, advancing beyond the hurdles
published pages: 535-545, ISSN: 1420-682X, DOI: 10.1007/s00018-015-2074-0
Cellular and Molecular Life Sciences 73/3 2019-07-24
2016 Paloma Juarez, Vikram Virdi, Ann Depicker, Diego Orzaez
Biomanufacturing of protective antibodies and other therapeutics in edible plant tissues for oral applications
published pages: n/a-n/a, ISSN: 1467-7644, DOI: 10.1111/pbi.12541
Plant Biotechnology Journal 2019-07-24

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNOFARM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNOFARM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

LiverMacRegenCircuit (2020)

Elucidating the role of macrophages in liver regeneration and tissue unit formation

Read More  

ROSETTA (2020)

Deciphering the Role of aberrant glycOSylation in the rEsponse to Targeted TherApies for breast cancer

Read More  

CYBERSECURITY (2018)

Cyber Security Behaviours

Read More